To observe the clinical efficacy and safety of Shuxuetong injection combined with sacubitril/valsartan tablets in the treatment of patients with cerebral infarction complicated with hypertension.

Patients with cerebral infarction complicated with hypertension admitted to our hospital were randomly divided into the treatment group and the control group according to the random number table method. The control group was given sacubitril/valsartan sodium tablets 100 mg each time, twice a day, orally. On the basis of the control group, the treatment group was given Shuxuetong injection 6 mL each time, once a day, intravenously. Both groups were treated for 2 weeks. The clinical efficacy, 24-hour average diastolic and systolic blood pressure, National Institutes of Health Stroke Scale (NIHSS) score, activities of daily living (ADL) score, hemorheology (whole blood viscosity, fibrinogen and hematocrit), blood lipids [total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C) levels], serum von Willebrand factor (vWF) and homocysteine (Hcy) levels of the patients in the two groups were compared, and the safety was evaluated.

This study ultimately included 92 patients, with 46 in the treatment group and 46 in the control group. After treatment, the total effective rates of the treatment group and the control group were 93.48% (43 cases/46 cases) and 78.26% (36 cases/46 cases), respectively. The treatment group was significantly higher than the control group (P<0.05). The NIHSS scores of the treatment group and the control group were (7.93±1.44) and (10.24±1.86) respectively; the ADL scores were (79.02±8.05) and (71.66±7.36) respectively. The NIHSS score of the treatment group was significantly lower than that of the control group (P<0.05), and the ADL score was significantly higher than that of the control group (P<0.05). The systolic blood pressure of the treatment group and the control group was (120.51±12.77) and (136.48±14.29) mmHg, respectively; the diastolic blood pressure was (80.36±9.66) and (89.74±11.02) mmHg, respectively; the whole blood viscosity was (4.69±0.59) and (7.16±0.84) mPa·s, respectively; the fibrinogen level was (3.17±0.65) and (4.41±1.02) g·L^-1, respectively; the hematocrit was 0.30±0.04 and 0.41±0.05, respectively; the total cholesterol level was (4.22±0.54) and (5.86±1.01) mmol·L^-1, respectively; the triglyceride level was (1.35±0.32) and (1.79±0.44) mmol·L^-1, respectively; the LDL-C level was (2.03±0.25) and (2.48±0.38) mmol·L^-1, respectively; the vWF level was (131.57±14.36)% and (144.74±14.61)%, respectively; the Hcy level was (12.32±1.48) and (18.62±2.09) μmol·L^-1, respectively. All the above indicators in the treatment group were significantly lower than those in the control group (all P< 0.05). The adverse reactions in the treatment group mainly included hypotension, hyperkalemia and bleeding. The adverse reactions in the control group mainly included hypotension, hyperkalemia and renal dysfunction. The total incidence of drug adverse reactions in the treatment group and the control group was 10.87% (5 cases/46 cases) and 8.70% (4 cases/46 cases) respectively. There was no statistically significant difference in the two group (P> 0.05).

For patients with cerebral infarction and hypertension, the treatment with Shuxuetong injection combined with sacubitril/valsartan sodium tablets shows better therapeutic effects initially. It can improve neurological function, enhance self-care ability, lower blood pressure and lipid levels, and improve hemorheology.